Skip to main content

Table 1 Comparison of the numerical background of D2T RA cases by treatment types. Subgroups are compared using one-way analysis of variance (ANOVA) for numerical variables and chi-squared test for categorical variables

From: Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

 

TNFi (N = 71)

IL-6Ri (N = 79)

CTLA4-Ig (N = 58)

JAKi (N = 145)

p

Mean

SE

Median

Mean

SE

Median

Mean

SE

Median

Mean

SE

Median

Numerical variables

 Age

63.5

1.8

67

68.6

1.2

70

64.6

1.6

67.5

60.5

1.1

63

< 0.01*

 Duration (months)

163.3

13.3

155

169.8

14.0

136

182.9

16.8

143

164.3

9.6

123

0.76

 CDAI

27.4

1.5

26.2

28.9

1.6

26.2

26.7

1.4

24.8

26.2

1.0

25

0.5

 HAQ-DI

1.6

0.1

1.5

1.6

0.1

1.6

1.6

0.1

1.6

1.4

0.1

1.4

0.19

 DAS28-CRP

4.9

0.1

5.0

5.0

0.1

4.7

4.6

0.1

4.5

4.5

0.1

4.6

0.05

 DAS28-ESR

5.7

0.1

5.8

5.9

0.1

5.8

5.3

0.2

5.2

5.2

0.1

5.4

< 0.01*

 GC dose (mg/day)a

1.2

0.3

0

1.3

0.3

0

1.5

0.3

0

1.1

0.2

0

0.75

 MTX dose (mg/week)

5.5

0.7

6

4.9

0.6

0

6.0

0.9

5

7.1

0.5

8

0.04

 Creatinine (mg/dL)

0.9

0.1

0.68

0.9

0.1

0.76

0.7

0.0

0.64

0.7

0.0

0.65

0.03*

Categorical variables

N

%

N

%

N

%

N

%

p

 Gender

Male

9

12.7

12

15.2

7

12.1

24

16.6

0.81

Female

62

87.3

67

84.8

51

87.9

121

83.4

 ACPA

Negative

10

14.1

17

21.5

9

15.5

34

23.4

0.36

Positive

57

80.3

57

72.2

49

84.5

111

76.6

 Disease activity

LDA

1

1.4

4

5.1

0

0.0

10

6.9

0.53

MDA

26

36.6

27

34.2

21

36.2

49

33.8

HDA

44

62.0

48

60.8

37

63.8

85

58.6

 Use of MTX

38

53.5

39

49.4

31

53.4

92

63.4

0.18

 Use of GC

19

26.8

16

20.3

19

32.8

29

20.0

0.20

 Chronic lung disease

25

35.2

32

40.5

20

34.5

41

28.3

0.31

 Chronic heart disease

2

2.8

12

15.2

2

3.4

2

0.7

< 0.01

 Osteoporosis with fracture

3

4.2

3

1.3

3

5.2

1

0.7

0.98

 Past use of b/tsDMARD

TL

20

28.2

1

1.3

45

77.6

43

29.7

N.A

TA

14

19.7

53

67.1

0

0.0

22

15.2

TJ

4

5.6

7

8.9

7

12.1

17

11.7

LA

6

8.5

0

0.0

0

0.0

5

3.4

LJ

2

2.8

0

0.0

0

0.0

0

0.0

AJ

0

0.0

1

1.3

0

0.0

0

0.0

TLA

20

28.2

0

0.0

0

0.0

24

16.6

TAJ

0

0.0

12

15.2

0

0.0

4

2.8

TLJ

1

1.4

2

2.5

6

10.3

11

7.6

TLAJ

4

5.6

3

3.8

0

0.0

19

13.1

 vD2T RA

25

35.2

17

21.5

6

10.3

58

40.0

< 0.01*

  1. D2T RA difficult-to-treat rheumatoid arthritis, b/tsDMARD targeted synthetic disease-modifying anti-rheumatic drugs, TNFi tumour necrosis factor inhibitor, IL-6R, interleukin-6 receptor inhibitor, CTLA4-Ig cytotoxic T-lymphocyte–associated antigen-4 immunoglobulin, JAKi Janus kinase inhibitor, CDAI Clinical Disease Activity Index, HAQ-DI Health Assessment Questionnaire Disability Index, DAS disease activity score, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MTX methotrexate, GC glucocorticoid, NA not applicable
  2. *p < 0.05
  3. a Prednisolone equivalent dose